Molecular Characterisation of Appendiceal Cancer
Characterisation of Appendiceal Cancer by Genomic and Transcriptomic Analysis and Correlation With Clinical Outcomes
1 other identifier
observational
100
1 country
1
Brief Summary
Patients ≥ 18 years old who have been diagnosed with appendiceal cancer with peritoneal metastases, have had cytoreductive surgery, have availability of archival tumour tissue and have consented to our institutional biobank program or have a waiver of consent for deceased patients who have not had the opportunity to provide biobank consent (requested at the time of ethics review). Descriptive analysis of the proportion of genetic mutations identified in appendiceal cancers. This is given by the percentage of pathogenic mutations in the peritoneal metastasis compared to the primary tumour.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 3, 2022
CompletedFirst Posted
Study publicly available on registry
May 6, 2022
CompletedStudy Start
First participant enrolled
February 4, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 3, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 3, 2025
CompletedJanuary 1, 2025
December 1, 2024
1.4 years
May 3, 2022
December 31, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Characterise the genes of appendiceal cancer.
Descriptive analysis of the proportion of genetic mutations identified in appendiceal cancers. This is given by the percentage of pathogenic mutations in the peritoneal metastasis compared to the primary tumour.
2 years
Secondary Outcomes (1)
Descriptive analysis in proportions
2 years
Study Arms (1)
All participants
Appendiceal Cancer Patients
Interventions
Acquisition of archival Formalin Fixed Paraffin Embedded (FFPE) human tissue from appendix cancer primary tumour and peritoneal metastases, which are stored in NHS pathology - taken from standard care biopsies.
Eligibility Criteria
Patients who have been diagnosed with appendiceal cancer with peritoneal metastases
You may qualify if:
- Participants are eligible to be included in the study only if all of the following criteria apply:
- Patients ≥ 18 years old who have been diagnosed with appendiceal cancer with peritoneal metastases,
- have had cytoreductive surgery
- have availability of archival tumour tissue
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The Christie NHS Foundation Trustlead
- University of Manchestercollaborator
Study Sites (1)
The Christie NHS Foundation Trust
Manchester, United Kingdom
Biospecimen
Archival Formalin Fixed Paraffin Embedded (FFPE) human tissue from appendix cancer primary tumour and peritoneal metastases.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 3, 2022
First Posted
May 6, 2022
Study Start
February 4, 2024
Primary Completion
July 3, 2025
Study Completion
July 3, 2025
Last Updated
January 1, 2025
Record last verified: 2024-12